NDC 73684-101
RELAFEN
Nabumetone
RELAFEN is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Blucrest Pharmaceuticals Llc. The primary component is Nabumetone.
| Product ID | 73684-101_18e2fc67-b13e-41bb-9781-751a1764bbb2 |
| NDC | 73684-101 |
| Product Type | Human Prescription Drug |
| Proprietary Name | RELAFEN |
| Generic Name | Nabumetone |
| Dosage Form | Tablet |
| Route of Administration | ORAL |
| Marketing Start Date | 2020-06-01 |
| Marketing Category | ANDA / ANDA |
| Application Number | ANDA203166 |
| Labeler Name | BLUCREST PHARMACEUTICALS LLC |
| Substance Name | NABUMETONE |
| Active Ingredient Strength | 750 mg/1 |
| Pharm Classes | Cyclooxygenase Inhibitors [MoA],Anti-Inflammatory Agents, Non-Steroidal [CS],Nonsteroidal Anti-inflammatory Drug [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
Packaging
NDC 73684-101-30
30 TABLET in 1 BOTTLE, PLASTIC (73684-101-30)
| Marketing Start Date | 2020-06-01 |
| NDC Exclude Flag | N |
| Sample Package? | N |
NDC SPL Data Element Entries
NDC 73684-101-30 [73684010130]
RELAFEN TABLET
| Marketing Category | ANDA |
| Application Number | ANDA203166 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2020-06-01 |
Drug Details
NDC Crossover Matching brand name "RELAFEN" or generic name "Nabumetone"
| NDC | Brand Name | Generic Name |
|---|---|---|
| 73684-100 | RELAFEN | RELAFEN |
| 80425-0053 | Relafen | Relafen |
| 73684-101 | RELAFEN | RELAFEN |
| 80425-0054 | Relafen | Relafen |
| 80425-0052 | Relafen | Relafen |
| 80425-0104 | Relafen | Relafen |
| 0115-1657 | Nabumetone | Nabumetone |
| 0115-1658 | Nabumetone | Nabumetone |
| 0440-5843 | Nabumetone | Nabumetone |
| 0440-5844 | Nabumetone | Nabumetone |
| 0591-3670 | Nabumetone | Nabumetone |
| 0591-3671 | Nabumetone | Nabumetone |
| 0615-7630 | Nabumetone | nabumetone |
| 0615-7645 | Nabumetone | nabumetone |
| 0615-7666 | Nabumetone | Nabumetone |
| 0615-7667 | Nabumetone | Nabumetone |
| 10544-003 | Nabumetone | Nabumetone |
| 10544-120 | Nabumetone | Nabumetone |
| 10544-271 | Nabumetone | Nabumetone |
| 10544-273 | Nabumetone | Nabumetone |
| 21695-230 | Nabumetone | Nabumetone |
| 21695-231 | Nabumetone | Nabumetone |
| 33261-077 | Nabumetone | Nabumetone |
| 33261-078 | Nabumetone | Nabumetone |
| 33358-251 | Nabumetone | Nabumetone |
| 33358-252 | Nabumetone | Nabumetone |
| 35356-686 | Nabumetone | Nabumetone |
| 35356-687 | Nabumetone | Nabumetone |
| 35356-726 | Nabumetone | Nabumetone |
| 43063-859 | Nabumetone | Nabumetone |
| 0722-7078 | Nabumetone 1000 mg | Nabumetone |
| 0722-7076 | Nabumetone 500 mg | Nabumetone |
| 0722-7077 | Nabumetone 750 mg | Nabumetone |
| 15370-170 | RELAFEN DS | NABUMETONE |
Trademark Results [RELAFEN]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 RELAFEN 87702292 not registered Live/Pending |
Argent Development Group, LLC 2017-11-29 |
 RELAFEN 86251872 not registered Dead/Abandoned |
Argent Development Group, LLC 2014-04-14 |
 RELAFEN 73353073 1248125 Dead/Cancelled |
Beecham Inc. 1982-03-04 |
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.